Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Vanguard Total Stock Market Index Fund ETF trades at $381.87 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 168869.3× Citius Pharmaceuticals Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| CTXR | VTI | |
|---|---|---|
Market Cap | $13.62M | $2.30T |
Volume | 132,438 | 2,982,924 |
Sector | Health | — |
52-Week High | $1.82 | $384.30 |
52-Week Low | $0.48 | $311.68 |
Typical Hold Time | 16 Days | 131 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
VTI trades at $380.52, down slightly by 0.13% with a bullish technical signal from moving averages. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains significant. Recent news highlights long-term growth potential with $500 monthly investments since 2001 growing to approximately $876,000 according to Motley Fool (2026-10-01).
VTI offers diversified U.S. market access with low costs, suitable for long-term investors. Risks include market concentration in top holdings and broader economic sensitivity. Analyst sentiment remains positive for buy-and-hold strategies, though recent articles question the value added by small/mid-cap exposure versus S&P 500-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
